Drug intelligence / Profile preview

gallium fibroblast activation protein inhibitor

Lead developer
SOFIE
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
Administration
Intravenous
01

Overview

Gallium fibroblast activation protein inhibitor (Ga-FAPI) refers to a class of target-specific diagnostic radiopharmaceuticals designed for positron emission tomography (PET) imaging. Developed originally by researchers at Heidelberg University Hospital and subsequently licensed to SOFIE Biosciences and GE HealthCare, these agents target fibroblast activation protein alpha (FAP), a cell-surface glycoprotein highly overexpressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment of various solid tumors, as well as on activated fibroblasts in chronic inflammatory and fibrotic diseases. Prominent members of this class include [68Ga]Ga-FAPI-04 and [68Ga]Ga-FAPI-46. By binding specifically to FAP, Ga-FAPI PET imaging provides high-contrast visualization of the tumor stroma and active fibrotic/inflammatory lesions with minimal background uptake in normal tissues, offering a promising alternative or complement to conventional [18F]FDG PET imaging. Ga-FAPI is currently being evaluated in clinical trials for staging and monitoring various malignancies (such as pancreatic, breast, and head and neck cancers) as well as chronic inflammatory and fibrosing conditions (including polymyalgia rheumatica, giant cell arteritis, rheumatoid arthritis, and liver fibrosis).

Other names
68Ga-FAPI68Ga-FAPI PETGa-FAPIGa-FAPI PETgallium Ga 68 fapigallium-68 fibroblast activation protein inhibitorgallium68 fibroblast activation protein inhibitorgallium 68 fibroblast activation protein inhibitorgallium-labeled fibroblast activation protein inhibitor
02

Identity

Drug type
Radiopharmaceuticals
Originator
Heidelberg University Hospital
Modality
Small MoleculesPeptidesAntibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
breast cancer and precursor lesionsIn developmentActive
endometriosisIn developmentActive
gastrointestinal cancers and precursor lesionsIn developmentActive
giant cell arteritis (GCA)In developmentActive
head and neck cancersIn developmentActive
liver fibrosis (hepatic fibrosis)In developmentActive
lung cancer and precursor lesionsIn developmentActive
pancreatic cancer and precursor lesionsIn developmentActive
polymyalgia rheumatica (PMR)In developmentActive
primary myelofibrosis (PMF)In developmentActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Heidelberg University HospitalOriginator
  • SOFIELead developer
07

Patents & exclusivity

Patents
2

Patent families, expiry dates and exclusivities are in the full profile.

08

Competitive landscape

Drugs on the same target
95
Drugs in the lead indication
1,053

Lead indication: breast cancer and precursor lesions

Most advanced in the lead indication

  1. cyclophosphamideApproved
  2. epirubicinApproved
  3. eribulinApproved
  4. fludeoxyglucose f 18Approved
  5. fluorouracilApproved

Beyond the preview

Go deeper on gallium fibroblast activation protein inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium fibroblast activation protein inhibitor.

Work on gallium fibroblast activation protein inhibitor? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call